These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 34438369)
1. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD. Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369 [TBL] [Abstract][Full Text] [Related]
2. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung. Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975 [TBL] [Abstract][Full Text] [Related]
3. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma. Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217 [TBL] [Abstract][Full Text] [Related]
4. A methylation-related lncRNA-based prediction model in lung adenocarcinomas. Yang K; Liu H; Li JH Clin Respir J; 2024 Aug; 18(8):e13753. PubMed ID: 39187946 [TBL] [Abstract][Full Text] [Related]
5. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma. Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484 [TBL] [Abstract][Full Text] [Related]
6. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD. Ma C; Gu Z; Yang Y J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237 [TBL] [Abstract][Full Text] [Related]
7. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma. Ren J; Wang A; Liu J; Yuan Q Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158 [TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature. Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988 [TBL] [Abstract][Full Text] [Related]
9. Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients. Liu J; Wu H; Gao Z; Lou M; Yuan K Bioengineered; 2021 Dec; 12(1):4123-4135. PubMed ID: 34288805 [TBL] [Abstract][Full Text] [Related]
10. Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma. Chen Y; Zhang X; Li J; Zhou M J Clin Lab Anal; 2021 Nov; 35(11):e24018. PubMed ID: 34550610 [TBL] [Abstract][Full Text] [Related]
11. Identification of a methyltransferase-related long noncoding RNA signature as a novel prognosis biomarker for lung adenocarcinoma. Sun YY; Li S; Liu C; Pan Y; Xiao Y Aging (Albany NY); 2024 May; 16(10):8747-8771. PubMed ID: 38771129 [TBL] [Abstract][Full Text] [Related]
12. Unlocking the Potential of Disulfidptosis-Related LncRNAs in Lung Adenocarcinoma: A Promising Prognostic LncRNA Model for Survival and Immunotherapy Prediction. Nie X; Ge H; Wu K; Liu R; He C Cancer Med; 2024 Oct; 13(20):e70337. PubMed ID: 39431755 [TBL] [Abstract][Full Text] [Related]
13. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study. Chen G; Dong Z; Wu D; Chen Y J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059 [TBL] [Abstract][Full Text] [Related]
14. An exosomes-related lncRNA prognostic model correlates with the immune microenvironment and therapy response in lung adenocarcinoma. Chu D; Chen L; Li W; Zhang H Clin Exp Med; 2024 May; 24(1):104. PubMed ID: 38761234 [TBL] [Abstract][Full Text] [Related]
15. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma. Jin D; Song Y; Chen Y; Zhang P Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372 [TBL] [Abstract][Full Text] [Related]
16. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma. Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375 [TBL] [Abstract][Full Text] [Related]
17. Characterization of an endoplasmic reticulum stress-associated lncRNA prognostic signature and the tumor-suppressive role of RP11-295G20.2 knockdown in lung adenocarcinoma. Yu L; Zhou S; Hong W; Lin N; Wang Q; Liang P Sci Rep; 2024 May; 14(1):12283. PubMed ID: 38811828 [TBL] [Abstract][Full Text] [Related]
18. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma. Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Yu L; Cao S; Li J; Han B; Zhong H; Zhong R Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738 [TBL] [Abstract][Full Text] [Related]
20. FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor. Yu L; Qiao R; Xu J; Han B; Zhong R Life Sci; 2021 Mar; 268():119022. PubMed ID: 33434533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]